Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06816992 · ClinicalTrials.gov registry record · Phase 1
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
A Phase 1 study of Solid Tumors and NSCLC, sponsored by ORIC Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 4
- Study locations
NCT06816992: Recruiting Phase 1 study of Solid Tumors and NSCLC, sponsored by ORIC Pharmaceuticals.
NCT06816992 is a Phase 1 study of Solid Tumors and NSCLC that is actively recruiting participants, run by ORIC Pharmaceuticals. The registered enrollment target is 76 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (73% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06816992, a Phase 1 study of Solid Tumors and NSCLC, is actively recruiting participants, sponsored by ORIC Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.
Primary Outcome
RP2D of ORIC-114 in combination with amivantamab by interval 3+3 dose escalation design
Conditions Studied
Interventions
- DRUG ORIC-114 Dose 1 + amivantamab
- DRUG ORIC-114 Dose 2 + amivantamab
- DRUG ORIC-114 Dose 3 + amivantamab
Study Locations (4)
New York
- NYU Langone Health - New York
Virginia
- Virginia Cancer Specialists - Fairfax
Victoria
- Peter MacCallum Cancer Centre - Melbourne
Ontario
- The Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-02-27 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What NCT06816992 shows while recruiting
NCT06816992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (73% lower).
The record links to 4 conditions, with Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which ORIC-114 Dose 1 + amivantamab is the first listed.
NCT06816992 reports a single indexed study location in New York, Virginia, Victoria.
Frequently Asked Questions
What is clinical trial NCT06816992 about?
NCT06816992 is a clinical study titled "ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC". The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 2...
What is the current status of trial NCT06816992?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2025-02-27. Estimated completion is 2027-05.
What conditions does trial NCT06816992 study?
This clinical trial studies the following conditions: Solid Tumors, NSCLC, EGFR Exon 20 Insertion Mutations, EGFR-mutated NSCLC.
What interventions are being tested in trial NCT06816992?
The interventions under investigation include: ORIC-114 Dose 1 + amivantamab (DRUG), ORIC-114 Dose 2 + amivantamab (DRUG), ORIC-114 Dose 3 + amivantamab (DRUG).
Who is sponsoring clinical trial NCT06816992?
This trial is sponsored by ORIC Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06816992 being conducted?
This trial has 4 study locations across New York, Virginia, Victoria, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06816992's enrollment target sits among peer trials
76 60th of 125 higher than 66 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI